ÂÜÀòÂÒÂ×

Craig S. Strasnick is a seasoned executive, experienced entrepreneur, and dynamic commercial leader. In his current role as President and CEO of Commonwealth Diagnostics International, Inc. (CDI), he partners with respected academics and industry leaders across the world to improve current gastroenterological practices. Craig drives the company’s mission by developing and introducing new patient-friendly preventative health and monitoring technologies, as well as ensuring their clinical and commercial execution. Craig graduated from Northeastern University with a degree in Business Administration. In 2021, Forbes named Craig Strasnick and Commonwealth Diagnostics International to the Forbes Next 1000.

Craig founded CDI in 2015 after securing the acquisition of Commonwealth Laboratories Inc., a company at which he previously founded and served as COO from 2011-2016. Serving as COO, he built the company over a six-year period from a two-employee firm to a thriving business with over 100 employees across all 50 states, and in Canada.

Craig continues to drive the company forward by working hard to bring new, innovative, and patient-centric preventative health and monitoring technologies to market that not only assist in enhancing the quality of life for the patients who use them but also create cost-effective solutions for the healthcare system overall and provide value-added services for the many healthcare providers who could benefit from their use.

Craig currently serves as a member of the Board of Directors of AlphaLogic, Inc., a company specializing in the development and commercialization of convenient, low-cost wearable sensory systems that can be deployed rapidly in the hospital, clinic, or at home for the diagnosis and ongoing monitoring of digestive wellness; as well as MyTotalHealth, Inc., a company that was founded to empower patients to monitor, manage, and understand their symptoms for a range of conditions both within GI as well as in other areas of medicine.

Additionally, he is a member of the Board of Directors of Functional Gut Diagnostics Ltd, CDI’s joint venture partner and sister company in the United Kingdom, which provides CDI’s entire portfolio of technologies to the UK market.